UNASSIGNED: A systematic search encompassing five electronic databases was conducted until July 30, 2023, to identify relevant systematic reviews (SRs) based on randomized controlled trials (RCTs) concerning Tai Chi for T2DM. The methodological quality of the included SRs was assessed using the A MeaSurement Tool to Assess systematic Reviews (AMSTAR 2) and the Risk of Bias in Systematic Reviews (ROBIS) tool. The Preferred Reporting Items for Overview of Systematic Review (PRIO-harms) checklist was used to promote a more balanced reporting of benefits and harms in this overview. Corrected covered area (CCA) was used to calculate the degree of overlapping primary studies. Primary outcome measures were glycosylated hemoglobin (HbA1c) and fasting blood glucose (FBG), while secondary outcomes encompassed health-related quality measures. The GRADE (Grades of Recommendations, Assessment, Development, and Evaluation) framework was utilized to assess the quality of evidence for the outcome measures.
UNASSIGNED: A total of 17 eligible SRs were included in this overview. One SR reported negative conclusions, while the remaining 16 reported positive ones on different outcomes. A total of 4 SRs reported adverse events, either absent or minor. Most of the SRs exhibited critically low quality (15/17) and a high risk of bias (14/17), as indicated by AMSTAR2 and ROBIS, respectively. The CCA was 12.14%, indicating a high degree of primary study overlapping. Evidence from 135 results for 24 outcomes concerning Tai Chi for T2DM was evaluated using the GRADE approach, most of which were rated very low.
UNASSIGNED: Tai Chi shows promise as a potentially effective and safe lifestyle intervention for adults with T2DM, particularly in improving HbA1c, FBG, BMI, and overall quality of life (QoL). However, these results should be cautiously interpreted due to methodological flaws observed in the current SRs and the low quality of the SRs based on GRADE. Furthermore, there is a compelling need for additional well-designed, high-quality RCTs and SRs to establish robust and conclusive evidence regarding the efficacy of Tai Chi for managing T2DM in the future.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD 42019140988.
■在2023年7月30日之前,进行了包含五个电子数据库的系统搜索,以基于有关太极拳治疗T2DM的随机对照试验(RCT)确定相关系统评价(SRs)。使用AMeaSurement工具评估系统评论(AMSTAR2)和系统评论中的偏倚风险(ROBIS)工具评估所包括SR的方法学质量。系统审查概述的首选报告项目(PRIO-harms)清单用于促进本概述中更平衡的利弊报告。校正后的覆盖面积(CCA)用于计算重叠的主要研究的程度。主要结局指标为糖化血红蛋白(HbA1c)和空腹血糖(FBG)。而次要结局包括与健康相关的质量指标.等级(建议等级,评估,发展,和评估)框架用于评估结果措施的证据质量。
■本概述中总共包括17个合格的SR。一位SR报告了负面结论,而其余16人报告了不同结局的阳性结果。共有4个SR报告了不良事件,缺席或轻微。大多数SR表现出严重低质量(15/17)和高偏见风险(14/17),如AMSTAR2和ROBIS所示,分别。CCA为12.14%,表明初级研究的高度重叠。使用GRADE方法评估了有关太极拳治疗T2DM的24个结局的135个结果的证据。其中大多数被评为非常低。
■太极拳有望成为成人T2DM患者的一种潜在有效且安全的生活方式干预措施。特别是在改善HbA1c方面,FBG,BMI,和整体生活质量(QoL)。然而,由于当前SRs中观察到的方法学缺陷以及基于GRADE的SRs质量较低,因此应谨慎解释这些结果。此外,迫切需要额外的精心设计,高质量的RCT和SRs,以建立关于太极拳在未来治疗T2DM的有效性的有力和确凿的证据。
■https://www.crd.约克。AC.英国/PROSPERO/,标识符CRD42019140988。